Evidence map›Paper›PMID 20566324›Full record

ArticleProtein expression and purification2010

Expression of neurotransmitter transporters for structural and biochemical studies.

Yael Elbaz, Tsafi Danieli, Baruch I Kanner, Shimon Schuldiner

Open access · greenAbstract read
In one paragraph

Article in Protein expression and purification, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  3. Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yael ElbazDepartment of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.
Tsafi Danieli
Baruch I Kanner
Shimon Schuldiner
Hebrew University of Jerusalem · IL

Funding

Yeast ExpressionP50GM073210 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STROUD, ROBERT M · 2004 to 2013
$21.5M
MOLECULAR MECHANISM OF ACTIVE NEUROTRANSMITTER TRANSPORTR01NS016708 · NINDS · HEBREW UNIVERSITY OF JERUSALEM · PI KANNER, BARUCH I, SCHULDINER, SHIMON · 1985 to 2014
$3.0M
Mechanisms of Active Neurotransmitter TransportR56NS016708 · NINDS · HEBREW UNIVERSITY OF JERUSALEM · PI KANNER, BARUCH I, SCHULDINER, SHIMON · 2009 to 2009
$306k
NIGMS NIH HHS P50 GM073210NIGMS NIH HHS P50 GM73210NINDS NIH HHS NS16708NINDS NIH HHS R01 NS016708NINDS NIH HHS R56 NS016708
6 · The paper itself

Abstract

Neurotransmitter transporters play essential roles in the process of neurotransmission. Vesicular neurotransmitter transporters mediate storage inside secretory vesicles in a process that involves the exchange of lumenal H(+) for cytoplasmic transmitter. Retrieval of the neurotransmitter from the synaptic cleft catalyzed by sodium-coupled transporters is critical for the termination of the synaptic actions of the released neurotransmitter. Our current understanding of the mechanism of these transporters is based on functional and biochemical characterization but is lacking high-resolution structural information. Very few structures of membrane transport systems from mammalian origin have been solved to atomic resolution, mainly because of the difficulty in obtaining large amounts of purified protein. Development of high yield heterologous expression systems suitable for mammalian neurotransmitter transporters is essential to enable the production of purified protein for structural studies. Such a system makes possible also the production of mutants that can be used in biochemical and biophysical studies. We describe here a screen for the expression of the vesicular monoamine transporter 2 (VMAT2) in cell-free and baculovirus expression systems and discuss the expression of VMAT2 in other systems as well (bacterial, yeast and mammalian cell lines). After screening and optimization, we achieved high yield (2-2.5 mg/l) expression of functional VMAT2 in insect cells. The system was also used for the expression of three additional plasma membrane neurotransmitter transporters. All were functional and expressed to high levels. Our results demonstrate the advantages of the baculovirus expression system for the expression of mammalian neurotransmitter transporters in a functional state.

Indexed as

AnimalsBaculoviridaeBiological TransportCell-Free SystemCells, CulturedFluorescent Antibody Technique, DirectGenetic VectorsImmunohistochemistryMembrane Transport ProteinsNeurotransmitter AgentsNeurotransmitter Transport ProteinsSpodopteraSynaptic TransmissionVesicular Monoamine Transport ProteinsMembrane Transport ProteinsNeurotransmitter AgentsNeurotransmitter Transport ProteinsVesicular Monoamine Transport Proteins

Identifiers

PMID20566324
PMCPMC2913170
OpenAlexW2115072720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.